Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Symptoms and General Pathology

Neoplasms

Gland and Hormone Related Diseases

Nutritional and Metabolic Diseases

Rare Diseases

Kidney Diseases

Renal Insufficiency, Chronic

Kidney Failure, Chronic

Renal Insufficiency

Neoplasm Metastasis

Hyperparathyroidism

Hyperparathyroidism, Secondary

Vitamin D Deficiency

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Chronic Disease

Disease Attributes

Neoplastic Processes

Avitaminosis

Deficiency Diseases

Malnutrition

Nutrition Disorders

Parathyroid Diseases

Endocrine System Diseases

Chronic Graft Versus Host Disease

Micronutrients

All Drugs and Chemicals

Bone Density Conservation Agents

Vitamins

Vitamin D

Cholecalciferol

Calcium

Alfacalcidol

Hydroxycholecalciferols

Calcium, Dietary

Trace Elements

Vitamin D3

Calciferol

alfacalcidol 16 weeks, 6 weeks wash out, paricalcitol 16 weeks

paricalcitol ´16 weeks, 6 weeks wash out, alfacalcidol 16 weeks

3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate

paricalcitol

1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.

alfacalcidol

Ditte Hansen, MD

The purpose of this study is to compare alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.

Secondary hyperparathyroidism is a common feature in patients with chronic kidney disease. Its clinical consequences include renal osteodystrophy, calciphylaxia and potentially vascular calcifications with increased morbidity and mortality.

Reduced synthesis of active vitamin D contributes to secondary hyperparathyroidism. Therefore we primarily manage this condition with activated vitamin D. In Denmark alfacalcidol is the primary choice of vitamin D analog.

However hypercalcemia and hyperphosphatemia may limit the use of alfacalcidol therapy due to increased risk of vascular calcification and mortality.

Therefore a new vitamin D analog, paricalcitol, has been developed, that may be less prone to develop hypercalcemia and hyperphosphatemia.

However a randomised controlled clinical study comparing alfacalcidol and paricalcitol has never been performed.

The primary objective of this study is to evaluate the effect of alfacalcidol and paricalcitol on intact parathyroid hormone level and the tendency towards hyperphosphatemia and hypercalcemia.

The study is performed in 117 patients with end stage renal failure on maintenance hemodialysis therapy in 6 different Danish hemodialysis units.

The design is a multicenter crossover study where patients are randomized into two treatment arms. After a wash out period of 6 weeks they are receiving alfacalcidol or paricalcitol for a period of 16 weeks and after a further wash out period of 6 weeks they receive the contrary treatment (respectively paricalcitol or alfacalcidol) for 16 weeks.

The initial dose of alfacalcidol (1 μg intravenously after dialysis) and paricalcitol (3 μg intravenously after dialysis) will be adjusted every second week based on iPTH, p-calcium and p-phosphate.

P-calcium, p-phosphate, iPTH, pulse and blood pressure are measured every second week. By the beginning and the end of each period of treatment, alkaline phosphatase, 25OH-D3, 1,25 (OH)2 vitamin D and safety parameters are measured, pulse wave velocity and pulse wave analysis is performed in a subgroup.

Alfacalcidol and paricalcitol are both registered treatment modalities for patients with renal failure and secondary hyperparathyroidism and should not perform any risk for the safety of the enrolled patients as well as the blood sampling and blood pressure measurement should not perform any risk either.

Treatment of Secondary Hyperparathyroidism in the Uremic Patient

Treatment of Secondary Hyperparathyroidism in the Uremic Patient. A Study Comparing Alfacalcidol and Paricalcitol

Zealand University Hospital

Ditte Hansen MD

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Treatment of Secondary Hyperparathyroidism in the Uremic Patient	NCT00469599	Secondary Hyper... Chronic Kidney ... Vitamin D Defic...	paricalcitol alfacalcidol	18 Years -	Zealand University Hospital
Treatment of Secondary Hyperparathyroidism in the Uremic Patient	NCT00469599	Secondary Hyper... Chronic Kidney ... Vitamin D Defic...	paricalcitol alfacalcidol	18 Years -	Zealand University Hospital

Spots Global Cancer Trial Database for renal osteodystrophy